259 related articles for article (PubMed ID: 20538380)
1. Synthesis and initial tumor affinity testing of iodine-123 labelled EGFR-affine agents as potential imaging probes for hormone-refractory prostate cancer.
Fozing T; Scheuer C; Samnick S
Eur J Med Chem; 2010 Sep; 45(9):3780-6. PubMed ID: 20538380
[TBL] [Abstract][Full Text] [Related]
2. Predictive efficacy of (11)C-PD153035 PET imaging for EGFR-tyrosine kinase inhibitor sensitivity in non-small cell lung cancer patients.
Dai D; Li XF; Wang J; Liu JJ; Zhu YJ; Zhang Y; Wang Q; Xu WG
Int J Cancer; 2016 Feb; 138(4):1003-12. PubMed ID: 26334931
[TBL] [Abstract][Full Text] [Related]
3. Metabolism of epidermal growth factor receptor targeting probe [11C]PD153035: impact on biodistribution and tumor uptake in rats.
Samén E; Arnberg F; Lu L; Olofsson MH; Tegnebratt T; Thorell JO; Holmin S; Stone-Elander S
J Nucl Med; 2013 Oct; 54(10):1804-11. PubMed ID: 24003078
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of radioiodinated quinazoline derivative as a new ligand for EGF receptor tyrosine kinase activity using SPECT.
Hirata M; Kanai Y; Naka S; Matsumuro K; Kagawa S; Yoshimoto M; Ohmomo Y
Ann Nucl Med; 2011 Feb; 25(2):117-24. PubMed ID: 21058048
[TBL] [Abstract][Full Text] [Related]
5. Imaging agents for in vivo molecular profiling of disseminated prostate cancer--targeting EGFR receptors in prostate cancer: comparison of cellular processing of [111In]-labeled affibody molecule Z(EGFR:2377) and cetuximab.
Malmberg J; Tolmachev V; Orlova A
Int J Oncol; 2011 Apr; 38(4):1137-43. PubMed ID: 21253675
[TBL] [Abstract][Full Text] [Related]
6. Preparation and tumor affinity testing of the radioiodinated tetrahydroisoquinoline derivative [123I]TIC(OH) for targeting prostate cancer.
Samnick S; Fozing T; Kirsch CM
Appl Radiat Isot; 2006 May; 64(5):563-9. PubMed ID: 16426853
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and evaluation of radioiodinated phenoxyquinazoline and benzylaminoquinazoline derivatives as new EGF receptor tyrosine kinase imaging ligands for tumor diagnosis using SPECT.
Hirata M; Kanai Y; Naka S; Matsumuro K; Kagawa S; Yoshimoto M; Ohmomo Y
Ann Nucl Med; 2012 Jun; 26(5):381-9. PubMed ID: 22354330
[TBL] [Abstract][Full Text] [Related]
8. Linking γ-aminobutyric acid A receptor to epidermal growth factor receptor pathways activation in human prostate cancer.
Wu W; Yang Q; Fung KM; Humphreys MR; Brame LS; Cao A; Fang YT; Shih PT; Kropp BP; Lin HK
Mol Cell Endocrinol; 2014 Mar; 383(1-2):69-79. PubMed ID: 24296312
[TBL] [Abstract][Full Text] [Related]
9. Combined targeting of epidermal growth factor receptor and MDM2 by gefitinib and antisense MDM2 cooperatively inhibit hormone-independent prostate cancer.
Bianco R; Caputo R; Caputo R; Damiano V; De Placido S; Ficorella C; Agrawal S; Bianco AR; Ciardiello F; Tortora G
Clin Cancer Res; 2004 Jul; 10(14):4858-64. PubMed ID: 15269162
[TBL] [Abstract][Full Text] [Related]
10. Androgen-independent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative HER receptors and ligands.
Carrión-Salip D; Panosa C; Menendez JA; Puig T; Oliveras G; Pandiella A; De Llorens R; Massaguer A
Int J Oncol; 2012 Sep; 41(3):1128-38. PubMed ID: 22684500
[TBL] [Abstract][Full Text] [Related]
11. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
[TBL] [Abstract][Full Text] [Related]
12. A pilot study on EGFR-targeted molecular imaging of PET/CT With 11C-PD153035 in human gliomas.
Sun J; Cai L; Zhang K; Zhang A; Pu P; Yang W; Gao S
Clin Nucl Med; 2014 Jan; 39(1):e20-6. PubMed ID: 24335566
[TBL] [Abstract][Full Text] [Related]
13. The DNA-binding epidermal growth factor-receptor inhibitor PD153035 and other DNA-intercalating cytotoxic drugs reactivate the expression of the retinoic acid receptor-beta tumor-suppressor gene in breast cancer cells.
Grunt TW; Tomek K; Wagner R; Puckmair K; Zielinski CC
Differentiation; 2007 Nov; 75(9):883-90. PubMed ID: 17608728
[TBL] [Abstract][Full Text] [Related]
14. Synergistic antiproliferative and apoptotic effects induced by epidermal growth factor receptor and protein kinase a inhibitors in human prostatic cancer cell lines.
Mimeault M; Pommery N; Hénichart JP
Int J Cancer; 2003 Aug; 106(1):116-24. PubMed ID: 12794766
[TBL] [Abstract][Full Text] [Related]
15. Improved synthesis of no-carrier-added p-[124I]iodo-L-phenylalanine and p-[131I]iodo-L-phenylalanine for nuclear medicine applications in malignant gliomas.
Israel I; Brandau W; Farmakis G; Samnick S
Appl Radiat Isot; 2008 Apr; 66(4):513-22. PubMed ID: 18024046
[TBL] [Abstract][Full Text] [Related]
16. 177Lu-AMBA biodistribution, radiotherapeutic efficacy, imaging, and autoradiography in prostate cancer models with low GRP-R expression.
Maddalena ME; Fox J; Chen J; Feng W; Cagnolini A; Linder KE; Tweedle MF; Nunn AD; Lantry LE
J Nucl Med; 2009 Dec; 50(12):2017-24. PubMed ID: 19910427
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic and preventive effects of an epidermal growth factor receptor inhibitor on oral squamous cell carcinoma.
Ge H; Liu H; Fu Z; Sun Z
J Int Med Res; 2012; 40(2):455-66. PubMed ID: 22613406
[TBL] [Abstract][Full Text] [Related]
18. Radiohalogenated 4-anilinoquinazoline-based EGFR-TK inhibitors as potential cancer imaging agents.
Neto C; Fernandes C; Oliveira MC; Gano L; Mendes F; Kniess T; Santos I
Nucl Med Biol; 2012 Feb; 39(2):247-60. PubMed ID: 22079040
[TBL] [Abstract][Full Text] [Related]
19. EGFR-SGLT1 interaction does not respond to EGFR modulators, but inhibition of SGLT1 sensitizes prostate cancer cells to EGFR tyrosine kinase inhibitors.
Ren J; Bollu LR; Su F; Gao G; Xu L; Huang WC; Hung MC; Weihua Z
Prostate; 2013 Sep; 73(13):1453-61. PubMed ID: 23765757
[TBL] [Abstract][Full Text] [Related]
20. EGFR signaling pathway negatively regulates PSA expression and secretion via the PI3K-Akt pathway in LNCaP prostate cancer cells.
Hakariya T; Shida Y; Sakai H; Kanetake H; Igawa T
Biochem Biophys Res Commun; 2006 Mar; 342(1):92-100. PubMed ID: 16472761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
